NDAINJECTIONINJECTABLE
Approved
Mar 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
14
Data completeness
5/8 — Partial
LYMPHOSEEK KIT (tilmanocept) by R-Pharm US is (technetium tc 99m tilmanocept) is a radioactive diagnostic agent. Approved for rheumatoid arthritis, breast cancer. First approved in 2013.
Drug data last refreshed 19h ago
Mechanism of Action
(technetium Tc 99m tilmanocept) is a radioactive diagnostic agent. It accumulates in lymphatic tissue and selectively binds to mannose binding receptors (CD206) located on the surface of macrophages and dendritic cells. Technetium Tc 99m tilmanocept is a macromolecule consisting of multiple units…
Indications (2)
Worked on LYMPHOSEEK KIT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.